Coherus Reports Q1 Revenue of $12.31M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Reports Q1 revenue $12.31M, consensus $14.34M. "We are executing well on our integrated financial, commercial and development strategy that maximizes LOQTORZI's potential in NPC and in combination with our pipeline products." said Denny Lanfear, Coherus Chairman and Chief Executive Officer. "We also continue to explore opportunities across cancers and non-proprietary novel combinations with tagmokitug, our potentially best-in-class CCR8 Treg depleter, and are encouraged given our previously reported clinical data including anti-tumor activity, safety data, tumor biomarker data and PK data."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CHRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CHRS
Wall Street analysts forecast CHRS stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.650
Low
4.00
Averages
5.50
High
7.00
Current: 1.650
Low
4.00
Averages
5.50
High
7.00
About CHRS
Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Coherus Oncology Q1 2026 Earnings Call Insights
- LOQTORZI Revenue Projections: CEO Dennis Lanfear stated that LOQTORZI is projected to generate about $175 million annually in nasopharyngeal cancer, with expectations of reaching $15 million per quarter in 2026 and $30 to $35 million per quarter in 2027, indicating strong market potential.
- R&D Spending and Financing: CFO Bryan McMichael reported Q1 2026 R&D expenses of $21.5 million and total net proceeds of $54 million, providing financial backing for future clinical trials and market expansion efforts.
- Sales Dynamics and Market Performance: Despite Q1 LOQTORZI net sales of $11.8 million, a decline from the previous quarter, CCO Sameer Goregaoker highlighted record new patient starts, demonstrating sustained market demand.
- Future Outlook and Data Releases: Management anticipates quarterly demand growth of 10% to 15% throughout 2026 and plans to provide full-year 2026 revenue guidance during the August earnings call, further bolstering investor confidence.
See More
CHRS Q1 2026 Earnings Transcript
See More
Coherus Oncology to Release Q1 2026 Financial Results on May 11
- Earnings Release Schedule: Coherus Oncology will release its Q1 2026 financial results after market close on May 11, which is expected to impact the company's future market performance.
- Management Conference Call: The management team will host a conference call at 5:00 p.m. ET on May 11 to discuss financial results and provide a business update, enhancing investor understanding of the company's strategy.
- Webcast Replay Availability: Investors can access a replay of the webcast on the company's website after the live call, ensuring transparency and compliance with regulatory requirements.
- Innovative Drug Pipeline: Coherus Oncology has a range of innovative oncology drugs, including the approved PD-1 inhibitor LOQTORZI®, and is advancing clinical candidates targeting various cancers, demonstrating the company's strategic positioning in cancer treatment.
See More
Coherus Oncology Reports Strong 2025 Financial Results
- Significant Revenue Growth: Coherus Oncology reported a net revenue of $40.8 million for 2025, a remarkable 113% increase from $19.1 million in 2024, indicating strong market acceptance of its next-gen PD-1 inhibitor, LOQTORZI, and suggesting enhanced future sales potential.
- Substantial Debt Reduction: The company successfully reduced its debt from $480 million to $38.8 million, a decrease of over 90%, significantly improving its financial position and providing greater funding flexibility for future R&D and market expansion.
- Increased R&D Spending: Despite overall cost control, Coherus raised its R&D expenses from $20.8 million to $31 million in Q4 2025, reflecting the company's commitment to new product development aimed at maintaining competitive advantage through innovation.
- Strong Cash Position: At the end of 2025, the company reported cash, cash equivalents, and investments totaling $172.1 million, ensuring financial stability for future operations and supporting potential strategic investments.
See More
Coherus Oncology Q4 2025 Earnings Call Highlights
- Successful Strategic Transformation: Coherus Oncology has completed its strategic pivot to focus on innovative oncology, acquiring Surface Oncology and reducing debt from $480 million to $38.8 million, a reduction of over 90%, significantly improving its financial position.
- LOQTORZI Sales Growth: LOQTORZI's net revenue reached $40.8 million in 2025, up 113% from $19.1 million in 2024, with expectations to achieve $175 million in annual revenue by 2028, capturing a 70% market share of a $250 million addressable market.
- Significant Cost Control: The company reported SG&A expenses of $23.6 million in Q4, down from $29.6 million in the same quarter last year, demonstrating substantial operational efficiency improvements, while R&D expenses increased to $31 million.
- Optimistic Future Outlook: Management anticipates a quarter-over-quarter demand growth of 10% to 15% for LOQTORZI and plans to provide revenue guidance for 2026 in the next earnings call, reflecting confidence in future market potential.
See More
Coherus BioSciences Reports Q4 Earnings Miss
- Earnings Miss: Coherus BioSciences reported a Q4 non-GAAP EPS of -$0.34, missing expectations by $0.03, indicating challenges in profitability that could undermine investor confidence.
- Revenue Growth Lag: Despite a 64.9% year-over-year revenue increase to $12.7M, the figure fell short of market expectations by $1.39M, reflecting competitive pressures that may impact future cash flows.
- Rating Downgrade: Analysts downgraded Coherus to 'Hold' due to potential advancements of the anti-CCR8 CHS-114, which may lower investor expectations for future growth and affect stock performance.
- Funding Initiative: Coherus Oncology announced a stock offering priced to raise $50.1M to support future R&D projects, a move that may dilute existing shareholders but provides essential funding for the company's growth initiatives.
See More
Coherus Oncology Q1 2026 Earnings Call Insights
- LOQTORZI Revenue Projections: CEO Dennis Lanfear stated that LOQTORZI is projected to generate about $175 million annually in nasopharyngeal cancer, with expectations of reaching $15 million per quarter in 2026 and $30 to $35 million per quarter in 2027, indicating strong market potential.
- R&D Spending and Financing: CFO Bryan McMichael reported Q1 2026 R&D expenses of $21.5 million and total net proceeds of $54 million, providing financial backing for future clinical trials and market expansion efforts.
- Sales Dynamics and Market Performance: Despite Q1 LOQTORZI net sales of $11.8 million, a decline from the previous quarter, CCO Sameer Goregaoker highlighted record new patient starts, demonstrating sustained market demand.
- Future Outlook and Data Releases: Management anticipates quarterly demand growth of 10% to 15% throughout 2026 and plans to provide full-year 2026 revenue guidance during the August earnings call, further bolstering investor confidence.
See More
CHRS Q1 2026 Earnings Transcript
See More
Coherus Oncology to Release Q1 2026 Financial Results on May 11
- Earnings Release Schedule: Coherus Oncology will release its Q1 2026 financial results after market close on May 11, which is expected to impact the company's future market performance.
- Management Conference Call: The management team will host a conference call at 5:00 p.m. ET on May 11 to discuss financial results and provide a business update, enhancing investor understanding of the company's strategy.
- Webcast Replay Availability: Investors can access a replay of the webcast on the company's website after the live call, ensuring transparency and compliance with regulatory requirements.
- Innovative Drug Pipeline: Coherus Oncology has a range of innovative oncology drugs, including the approved PD-1 inhibitor LOQTORZI®, and is advancing clinical candidates targeting various cancers, demonstrating the company's strategic positioning in cancer treatment.
See More
Coherus Oncology Reports Strong 2025 Financial Results
- Significant Revenue Growth: Coherus Oncology reported a net revenue of $40.8 million for 2025, a remarkable 113% increase from $19.1 million in 2024, indicating strong market acceptance of its next-gen PD-1 inhibitor, LOQTORZI, and suggesting enhanced future sales potential.
- Substantial Debt Reduction: The company successfully reduced its debt from $480 million to $38.8 million, a decrease of over 90%, significantly improving its financial position and providing greater funding flexibility for future R&D and market expansion.
- Increased R&D Spending: Despite overall cost control, Coherus raised its R&D expenses from $20.8 million to $31 million in Q4 2025, reflecting the company's commitment to new product development aimed at maintaining competitive advantage through innovation.
- Strong Cash Position: At the end of 2025, the company reported cash, cash equivalents, and investments totaling $172.1 million, ensuring financial stability for future operations and supporting potential strategic investments.
See More
Coherus Oncology Q4 2025 Earnings Call Highlights
- Successful Strategic Transformation: Coherus Oncology has completed its strategic pivot to focus on innovative oncology, acquiring Surface Oncology and reducing debt from $480 million to $38.8 million, a reduction of over 90%, significantly improving its financial position.
- LOQTORZI Sales Growth: LOQTORZI's net revenue reached $40.8 million in 2025, up 113% from $19.1 million in 2024, with expectations to achieve $175 million in annual revenue by 2028, capturing a 70% market share of a $250 million addressable market.
- Significant Cost Control: The company reported SG&A expenses of $23.6 million in Q4, down from $29.6 million in the same quarter last year, demonstrating substantial operational efficiency improvements, while R&D expenses increased to $31 million.
- Optimistic Future Outlook: Management anticipates a quarter-over-quarter demand growth of 10% to 15% for LOQTORZI and plans to provide revenue guidance for 2026 in the next earnings call, reflecting confidence in future market potential.
See More
Coherus BioSciences Reports Q4 Earnings Miss
- Earnings Miss: Coherus BioSciences reported a Q4 non-GAAP EPS of -$0.34, missing expectations by $0.03, indicating challenges in profitability that could undermine investor confidence.
- Revenue Growth Lag: Despite a 64.9% year-over-year revenue increase to $12.7M, the figure fell short of market expectations by $1.39M, reflecting competitive pressures that may impact future cash flows.
- Rating Downgrade: Analysts downgraded Coherus to 'Hold' due to potential advancements of the anti-CCR8 CHS-114, which may lower investor expectations for future growth and affect stock performance.
- Funding Initiative: Coherus Oncology announced a stock offering priced to raise $50.1M to support future R&D projects, a move that may dilute existing shareholders but provides essential funding for the company's growth initiatives.
See More
